FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
wasinington,	D.C.	20049

STATEMENT	OF CHANGES II	N BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Walker Neal					2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ ACRS ]							(Ch	eck all applic	all applicable) Director		p Person(s) to Issuer  10% Owner	
	,	First) ERAPEUTICS, I JITE 200	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/01/2020							below)	Officer (give title below)  President and Cl			specify	
(Street) WAYNE		A State)	19087 (Zip)	4	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	e) <mark>X</mark> Form fi	Joint/Group Filing (Check Applicable filed by One Reporting Person filed by More than One Reporting n			
		Та	ıble I - Non	-Derivat	ive S	ecuriti	es Acq	uired,	Dis	posed of	, or Ben	eficiall	y Owned				
1. Title of Security (Instr. 3)			Date	. Transaction ate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)				4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amour Securitie Beneficia Owned F	s ally ollowing	Form (D) or	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)	(s) 4)		(IIISU. 4)
Common Stock				09/01/2	/2020		М		83,092	A	(1)	1,17	1,170,023		D		
Common	Common Stock 09/0			09/01/2	/2020		F <sup>(2)</sup>		23,872	D	\$2.3	3 1,14	1,146,151		D		
			Table II - E							osed of, onvertib			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Code	Saction (Instr. Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ion Da				8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(s)		
Restricted stock units	(1)	09/01/2020		A		83,092		(3)		(3)	Common Stock	83,092	\$0.00	83,09	2	D	
Restricted stock units	(1)	09/01/2020		М			83,092	(3)		(3)	Common Stock	83,092	\$0.00	0		D	

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 2. The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.
- 3. The shares underlying these restricted stock units vest immediately.

## Remarks:

/s/ Mark Ballantyne, Attorneyin-fact \*\* Signature of Reporting Person

Date

09/03/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.